iomeron 300 mg/ml solution for injection
bracco imaging s.p.a. - iomeprol - 300 mg/ml solution for injection
iomeron 350 mg/ml solution for injection
bracco imaging s.p.a. - iomeprol - 350 mg/ml solution for injection
iomeron 400 mg/ml solution for injection
bracco imaging s.p.a. - iomeprol - 400 mg/ml solution for injection
iopamiro 300 mg/ml solution for injection
bracco imaging s.p.a. - iopamidol - 300 mg/ml solution for injection
iopamiro 370 mg/ml solution for injection
bracco imaging s.p.a. - iopamidol - 370 mg/ml solution for injection
ibuprofen b. braun 600 mg/100 ml solution for infusion
600 mg/100 ml solution for infusion
ibuprofen b. braun 400 mg/100 ml solution for infusion
400 mg/100 ml solution for infusion
ondansetron b. braun 0,08 mg/ml solution for infusion
0,08 mg/ml solution for infusion
rocuronium b. braun 10 mg/ml solution for injection/infusion
10 mg/ml solution for injection/infusion
pemetrexed pfizer (previously pemetrexed hospira)
pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - Антинеопластични средства - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.